
Omnicell, Inc.
- Jurisdiction
United States - LEI
5493008RH0GTKHHPZI77 - ISIN
US68213N1090 (OMCL )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€33.29 31.1% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Read full profile
Stock price
Fundamentals
- Net revenue
€986.30M - Gross margin
43.7% - EBIT
€13.27M - EBIT margin
1.3% - Net income
€19.81M - Net margin
2.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
N/A | N/A |
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 2, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |